Gene test reduces the breast cancer danger

10/10/2017 03:00 |

Gene test reduces the breast cancer danger

"That's the difference between mastectomy, lumpectomy, the difference between chemotherapy or no chemotherapy".

Approximately 550 women will die each year in CT from breast cancer. While this is the figure given to all women with a BRCA gene mutation, experts say that cancer risks are more complicated than that, and vary from person to person.

In addition to the Methylobacterium finding, the team discovered that cancer patients' urine samples had increased levels of gram-positive bacteria, including Staphylococcus and Actinomyces.

"We know that numerous women who are receiving (double) mastectomy do not have advanced tumors that require mastectomy even on the affected side", said lead study author Dr. Reshma Jagsi of the University of MI in Ann Arbor.

Published online in the journal Oncotarget, the study examined the tissues of 57 patients who underwent mastectomy for breast cancer or cosmetic breast surgery. More than 70% of the cases present in advanced stage accounting for poor survival and high mortality. It has become necessary to inform all about breast cancer as it is the second most common type of cancer found in women.

29-percent of women who missed more than a month of work lost more than $5,000 in income. Another limitation of the study is that researchers lacked data on why women missed work, and it's possible some of that time wasn't related to the type of treatment they received. "The impact of treatment on employment and finances is a consideration that women may wish to take into account when weighing the pros and cons of various surgical options they are considering". That is the figure estimated to all women with a BRCA gene mutation. All treatments are individualized for what that particular patient needs.

Talk to your doctor about what factors are increasing your risk for developing a breast cancer.


Add comment